Scarica l'app Stockscreener
58.88
0.79%
-0.47
Dopo l'orario di chiusura:
58.88
Xenon Pharmaceuticals Inc Borsa (XENE) Ultime notizie
Xenon to Present at Upcoming Investor Conferences - Yahoo Finance
Xenon Expands 2025 Inducement Equity Incentive Plan - The Globe and Mail
Xenon Pharmaceuticals Amends 2025 Inducement Equity Incentive Plan for Nasdaq Compliance and Employee Attraction 10 - Minichart
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve - Stock Titan
Certain Restricted Stock Units of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Stock Options of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Certain Common Shares of Xenon Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 10-APR-2026. - marketscreener.com
Published on: 2026-04-09 12:46:57 - baoquankhu1.vn
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN By Investing.com - Investing.com Australia
Xenon Pharmaceuticals to present azetukalner epilepsy data at AAN - Investing.com
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting - Bitget
Xenon brings 48-month epilepsy drug data and Phase 3 results to AAN - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - AOL.com
XENE SEC FilingsXenon Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Aberdeen Group plc Increases Stock Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) climbs 31.7% as epilepsy treatment moves forward - MSN
XENE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
XENE PE Ratio & Valuation, Is XENE Overvalued - Intellectia AI
Xenon Pharmaceuticals Inc.Common Shares (NQ: XENE - The Chronicle-Journal
XENE Should I Buy - Intellectia AI
Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE) - MarketBeat
Xenon Pharmaceuticals stock soars 20% in 3 months: Here's why - MSN
How Positive Phase 3 Azetukalner Results and Upsized Financing Could Reframe Xenon Pharmaceuticals (XENE) Investors - Sahm
Assenagon Asset Management S.A. Invests $5.34 Million in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Assessing Xenon Pharmaceuticals (XENE) Valuation After Positive Phase 3 Results And US$750 Million Capital Raise - Sahm
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool
Xenon Pharmaceuticals (XENE) price target increased by 41.64% to 80.01 - MSN
Wolfe Research initiates coverage of Xenon Pharmaceuticals (XENE) with outperform recommendation - MSN
Crude oil rises around 4%; Xenon Pharmaceuticals shares surge - MSN
(XENE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Published on: 2026-03-22 04:08:37 - baoquankhu1.vn
Xenon Pharmaceuticals rallies after pivotal data shows major drop in monthly seizures - MSN
Xenon Pharmaceuticals stock faces pipeline scrutiny amid biotech sector volatility - AD HOC NEWS
JPMorgan Chase & Co. Purchases 142,452 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals Shares Jump 20% Over Three Months: The Reasons Explained - Bitget
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why - The Globe and Mail
Investors Buy High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE) - MarketBeat
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):